When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
EDSA - Edesa Biotech Pushes Forward To Phase 2b Study For Lead Clinical Product
Edesa Biotech Inc.
Edesa Biotech (EDSA) is having a good 2019 so far. That's because it received the go-ahead from the FDA to initiate a phase 2b study using its treatment EB01 for patients with chronic contact dermatitis. The stock has made remarkable progress gaining about 592% year to date. It is using its topical treatments to target other skin disorders at the root cause of the disease and then possibly branch out its treatment to gastrointestinal diseases as well. Most of the pipeline is in the early stage of clinical development, but for now, this